25.45
Schlusskurs vom Vortag:
$25.56
Offen:
$25.4
24-Stunden-Volumen:
2,268
Relative Volume:
0.36
Marktkapitalisierung:
$N/A
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-0.16%
1M Leistung:
+0.20%
6M Leistung:
+0.43%
1J Leistung:
-0.59%
Xoma Corporation Stock (XOMAO) Company Profile
Firmenname
Xoma Corporation
Sektor
Branche
Telefon
510 204 7200
Adresse
2200 Powell Street, Suite 310, EmeryVille
Vergleichen Sie XOMAO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
XOMAO
Xoma Corporation
|
25.45 | 0 | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.38 | 114.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
748.71 | 78.80B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
396.04 | 51.80B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
847.05 | 53.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
166.55 | 42.33B | 447.02M | -1.18B | -906.14M | -6.1812 |
Xoma Corporation Aktie (XOMAO) Neueste Nachrichten
Can XOMA Royalty Corporation stock double in next 5 yearsWeekly Trade Review & Free Risk Controlled Daily Trade Plans - Улправда
Jefferies downgrades Generation Bio stock to Hold as XOMA acquisition announced By Investing.com - Investing.com South Africa
Generation Bio is latest Mass. biotech to be acquired by Xoma - The Business Journals
XOMA to buy struggling Generation Bio - The Pharma Letter
Jefferies downgrades Generation Bio stock to Hold as XOMA acquisition announced - Investing.com Nigeria
‘Zombie’ biotech buyer Xoma to acquire Generation Bio - Yahoo Finance
XOMA Strikes Deal To Acquire Generation Bio, Expanding Royalty Portfolio - Nasdaq
XOMA Royalty to Acquire Generation Bio - citybiz
Generation Bio Announces Merger with XOMA Royalty - TipRanks
Xoma Royalty enters into agreement to acquire Generation Bio - marketscreener.com
XOMA Royalty Corporation to Acquire Generation Bio Co. in Cash Transaction with Milestone and Royalty Opportunities - Quiver Quantitative
Generation Bio (NASDAQ: GBIO) agrees to $4.29 sale to XOMA Royalty plus CVR - Stock Titan
Investors Don't See Light At End Of XOMA Royalty Corporation's (NASDAQ:XOMA) Tunnel - simplywall.st
Generation Bio (GBIO) to be acquired in planned XOMA tender offer - Stock Titan
FY2025 EPS Estimates for XOMA Royalty Reduced by Analyst - MarketBeat
XOMA Royalty Corporation: A Deep Dive into a Biotech Royalty Aggregator (12/13/2025) - Markets Financial Content
BVF Inc. IL Has $65.28 Million Stock Position in XOMA Royalty Corporation $XOMA - MarketBeat
Why (XOMAO) Price Action Is Critical for Tactical Trading - news.stocktradersdaily.com
Price-Driven Insight from (XOMA) for Rule-Based Strategy - news.stocktradersdaily.com
XOMA stock maintains Buy rating at Benchmark despite partner’s trial setback - Investing.com
XOMA: HC Wainwright Maintains Buy Rating, Lowers Price Target to $97 | XOMA Stock News - GuruFocus
Leerink Partners lowers XOMA stock price target on RZ358 trial failure By Investing.com - Investing.com South Africa
HC Wainwright & Co. Maintains XOMA Royalty (XOMA) Buy Recommendation - Nasdaq
HC Wainwright & Co. Maintains XOMA Royalty CorporationPreferred Stock (XOMAP) Buy Recommendation - Nasdaq
Why two Bay Area companies' stocks tumbled on a drug's clinical failure - The Business Journals
XOMA stock price target lowered to $97 by H.C. Wainwright - Investing.com Australia
XOMA Royalty Corporation (NASDAQ:XOMA) Receives Average Rating of "Hold" from Brokerages - MarketBeat
XOMA: Leerink Partners Lowers Price Target, Reiterates Outperfor - GuruFocus
Why Is XOMA Royalty Stock Sinking Thursday? - Benzinga
Leerink Partners lowers XOMA stock price target on RZ358 trial failure - Investing.com
LUCID CAPITAL MARKETS Initiates Coverage of XOMA Royalty CorporationPreferred Stock (XOMAP) with Buy Recommendation - Nasdaq
LUCID CAPITAL MARKETS Initiates Coverage of XOMA Royalty (XOMA) with Buy Recommendation - Nasdaq
Lucid Capital Markets initiates coverage on XOMA stock with Buy rating - Investing.com Canada
XOMA Royalty (XOMA): New Buy Rating Initiated by Lucid Capital M - GuruFocus
Xoma initiated with a Buy at Lucid Capital - TipRanks
CEO’s Bold Move: Massive Investment in Xoma Stock! - TipRanks
Insider Buying: XOMA Royalty (NASDAQ:XOMA) CEO Acquires 100,000 Shares of Stock - MarketBeat
XOMA Royalty Corp CEO Owen Hughes Acquires 100,000 Depositary Shares - TradingView
Xoma Royalty Expands Portfolio Through Mural Oncology Acquisition - AD HOC NEWS
XOMA Royalty completes acquisition of Mural Oncology for $2.035 per share - Investing.com Nigeria
XOMA Royalty completes acquisition of Mural Oncology By Investing.com - Investing.com Nigeria
Xoma Completes Acquisition of Mural Oncology - TipRanks
Xoma announces closing of transaction to acquire Mural Oncology - TipRanks
XOMA Royalty completes acquisition of Mural Oncology for $2.035 per share By Investing.com - Investing.com South Africa
Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of Acquisition - Research Tree
Xoma Royalty announces closing of transaction to acquire Mural Oncology plc - marketscreener.com
XOMA Royalty Corporation Completes Acquisition of Mural Oncology plc Under Irish High Court Sanctioned Scheme - Quiver Quantitative
XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc - The Manila Times
XOMA Royalty (Nasdaq: XOMA) completes $2.035 per share Mural Oncology takeover - Stock Titan
XOMA Royalty completes acquisition of Mural Oncology - Investing.com India
Mural Oncology plc Announces Effective Date of Scheme Arrangement for Acquisition by XOMA Royalty Corporation - Quiver Quantitative
Finanzdaten der Xoma Corporation-Aktie (XOMAO)
Es liegen keine Finanzdaten für Xoma Corporation (XOMAO) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Kapitalisierung:
|
Volumen (24h):